Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership

TIANJIN, China, May 13, 2010 - A signing ceremony for a strategic partnership agreement between Tianjin
International Joint Academy of Biotechnology and Medicine (TJAB) and Genzyme
Corporation was held in the Tianjin Economic-Technological Development Area
(TEDA) on 10 May.

Officials and executives including Rao Zihe, President of TJAB and
President of Nankai University, He Shushan, Director of TEDA Administrative
Commission and Standing Committee Member of the CPC Committee of the Binhai
New Area, Li Baochun, Deputy Director of the Tianjin Municipal Science and
Technology Commission, Huang Yalou, Director of the Binhai New Area Science
and Technology Commission, Zhang Yaozhou, Vice president of TJAB, Richard
Gregory, Senior VP and Head of Research, Genzyme, Canwen Jiang, Vice
President and Head of R&D Asia, Genzyme, and Shan Jizhong, General Manager of
Genzyme Beijing Biotechnology Co. Ltd, attended the signing ceremony.

Genzyme is one of the world's ten leading biotechnology companies. The
company has grown to a diversified enterprise with more than 12,000 employees
in locations spanning the globe and 2009 revenues of US$4.5 billion. The
company is committed to developing and applying the most advanced
technologies in life sciences, with the research and development efforts
spanning a range of medical areas including cardiovascular disease.

TJAB, co-founded by the Ministry of Science and Technology, the Ministry
of Commerce, the Ministry of Health, the State Food and Drug Administration
and the Tianjin Municipal People's Government, officially opened in June
2009. As the core and symbol of the BioMed Zone, the academy received RMB1.1
billion of investment from the Tianjin Binhai New Area which was used to
install specialized apparatus and devices. Leveraging its one-stop service
system and dedicated public technology platform, TJAB has been committed to
accelerating the process from new drug development to industrialization.

The strategic partnership between TJAB and Genzyme in the fields of
application and translational research, preclinical and clinical study,
diagnostic testing and therapy, as well as doctoral and postdoctoral
education training will help quickly and successfully bring the company's
innovative drugs to China, promoting innovation and development of the
Chinese biopharmaceutical industry.

Ms. Wang Qian, +86-22-2520-1567